Navigation Links
MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
Date:7/13/2009

l likely remain an important cause of neurological disease for the foreseeable future. Since 2002, more than 4,500 cases of clinical WNV infection have been reported in Canada. No effective therapy or vaccine is available for humans. For more information about WNV, including maps of WNV activity, please visit www.cdc.gov/WestNile.

About MacroGenics, Inc.

MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in monoclonal antibody product development. The company's product development efforts leverage three proprietary technology platforms: (1) cancer stem-like cells; (2) Dual Affinity Re-Targeting (DART), which allows the company to incorporate multiple specificities within a single molecule; and (3) Fc optimization, which enhances antibody-dependent effector functions. These powerful sets of capabilities and technology platforms have enabled MacroGenics to build a proprietary pipeline of innovative product candidates. The company's lead program, teplizumab, is an anti-CD3 antibody being developed for the treatment of autoimmune diseases. In October 2007, MacroGenics and Eli Lilly announced a global strategic alliance to develop and commercialize teplizumab as well as other potential next-generation anti-CD3 molecules. For more information about MacroGenics, please visit www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions a
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Paulo F. Costa Joins MacroGenics Board of Directors
2. MacroGenics Appoints New Vice President of Business Development
3. MacroGenics Raises $25M in Series D-2 Financing
4. MacroGenics Acquires Raven Biotechnologies
5. Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
6. China-Biotics, Inc. Announces Conference Call to Discuss Fourth Quarter and Full Year 2009 Financial Results
7. Mirixa Corporation Announces Key New Hires
8. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
9. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
10. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
11. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... Biotechnology Company, Limited ("TaiGen") today announced that they have ... pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ® ... Turkey and other members of ... for the treatment of bacterial infections including those caused ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... Alliance, an,organization comprised of 12 of the nation,s best ... million Americans to exercise,their power over cancer by stepping ... Day through Father,s Day., The campaign, dubbed the ... activate Americans everywhere to take matters into their own,hands, ...
... Genaera,Corporation (Nasdaq: GENR ) today announced its financial ... for the quarter ended March 31,2008 was $4.3 million, or ... loss of $4.2 million, or $(0.24) per basic and diluted ... and development expenses for the quarter ended March,31, 2008 were ...
... ,Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... scheme of,arrangement proposed in a circular to shareholders ... a meeting convened by the Court and,held today., ... 2008, the High Court is expected to,approve the ...
Cached Biology Technology:Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research 2Genaera Corporation Announces First Quarter Financial Results 2Genaera Corporation Announces First Quarter Financial Results 3Genaera Corporation Announces First Quarter Financial Results 4Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 2Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 3Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 4Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans 5
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
(Date:4/17/2014)... Medical Branch at Galveston are the first to ... cervical cancer should begin colorectal cancer screening earlier ... finding a high incidence of secondary colorectal cancers ... new recommendations that the younger women in this ... after their initial cervical cancer diagnosis instead of ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Radiation therapy for cervical cancer increases risk for colorectal cancer 2
... The National Science Foundation has awarded Iowa State ... million grant to establish the NSF Engineering Research ... The award is part of the National ... Program. The third-generation Engineering Research Centers are designed ...
... utilize small, short-lived animals (insects, worms, mice) under ... parasites, superabundant food in the laboratory. Oddly ... such animals in their harsh, stressful natural environments. ... actually age much more slowly in captive luxury ...
... Bats, ability to echolocate may have evolved more than once, ... of London scientists. Species of bat with the ability ... tree of life - some are more related to their ... of whether echolocation in bats has evolved more than once, ...
Cached Biology News:Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 2Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 3Iowa State wins $18.5M grant to create NSF Center for Biorenewable Chemicals 4Old before their time? Aging in flies under natural vs. laboratory conditions 2Molecular evolution is echoed in bat ears 2
... 200 IS System is ideal for developing ... reagents. This system contains the new, improved, ... Luminex. The user can design specific templates ... system has fully integrated graphing and data ...
... The GeneSwitch Cell Lines stably express ... Each cell line is functionally tested ... with the expression control vector pGene/V5-His/lacZ ... after treatment with mifepristone (Figure 1). ...
... 15-20 enhancements when used as directed, ... is designed to amplify the desired signal detected by ... proteins with low expression., Membrane Enhancement ... the membrane; 1x solution; 250 ml, ...
... library screening, optimal siRNA transfection ... verified for each cell type ... Transfection Optimization Kit, which was ... conditions in 96 well plates, ...
Biology Products: